Document is current
Any future updates will be listed below
-
Authors
Avouac, Jérôme
Barzel, Adi https://orcid.org/0000-0001-8490-7002
Caiati, Delma
Davis, Randall S.
Gottschalk, Stephen https://orcid.org/0000-0003-3991-7468
Grieshaber-Bouyer, Ricardo https://orcid.org/0000-0002-2873-5135
Mao, Xuming
Luning Prak, Eline T. https://orcid.org/0000-0002-9478-9211
Radic, Marko https://orcid.org/0000-0002-8004-282X
Scherlinger, Marc https://orcid.org/0000-0002-9453-5895
Suneja, Yatin
Talleur, Aimee
Thacker, Amber L.
Unutmaz, Derya
- License Information
-
More Information
Article History
Accepted: 18 November 2025
First Online: 26 January 2026
Competing interests
: M.S. is a consultant for Abbvie, Amgen, AstraZeneca, Biogen, BMS, Fresenius, Galapagos, GSK, Innate Pharma, Nordic Pharma, Novartis, Roche and Sandoz. S.G. is a member of the Data Safety Monitoring Board (DSMB) of Immatics, serves on the Scientific Advisory Board of Be Biopharma, served as a consultant for CARGO Therapeutics within the last 12 months, and has patents and patent applications in the fields of T cell and/or gene therapy for cancer. M.R. has consulted for Bain Capital, Guidepoint Global LLC and NVP Associates. The other authors declare no additional competing interests.
